NXL insider transaction filings

Nexalin Technology, Inc. — 20 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-23. Screen NXL transaction legs live →

FiledFormInsiderReported transactionsSource
2025-12-234White Mark — CEO, DirectorGrant/award (A): 1,000,000 (derivative) @ $0EDGAR
2025-12-234Van Fleet Justin — CFOGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-12-234Owens David — Chief Medical Officer, DirectorGrant/award (A): 1,000,000 (derivative) @ $0EDGAR
2025-12-234Shelton Carolyn Hamby — Sr. VP - Quality - RegulatoryGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-12-234Hu Ben — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-12-234Kazden Alan — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2025-09-304Owens David — Chief Medical Officer, DirectorGrant/award (A): 36,459 @ $0EDGAR
2025-09-304Hu Ben — DirectorGrant/award (A): 36,459 @ $0EDGAR
2025-09-304Kazden Alan — DirectorGrant/award (A): 36,459 @ $0EDGAR
2025-09-304OSSER LEONARD — 10% owner
Elson Marilyn
Grant/award (A): 83,333 @ $0EDGAR
2025-09-124Shelton Carolyn Hamby — Sr. VP - Quality - RegulatoryGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-09-124Owens David — Chief Medical Officer, DirectorGrant/award (A): 203,125 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2025-09-124Elson Marilyn — 10% owner
OSSER LEONARD — 10% owner
Sale (S): 23,150 (derivative) @ $0.02EDGAR
2025-07-214Elson Marilyn — 10% owner
OSSER LEONARD
Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2025-03-134Shelton Carolyn Hamby — Sr. VP - Quality, RegulatoryPurchase (P): 6,000 @ $2.20EDGAR
2025-02-274White Mark — President and CEO, DirectorGrant/award (A): 447,427 (derivative) @ $0 · Grant/award (A): 939,597 (derivative) @ $0EDGAR
2025-02-274Owens David — Chief Medical Officer, DirectorGrant/award (A): 139,821 (derivative) @ $0 · Grant/award (A): 654,363 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0EDGAR
2025-02-054Owens David — Chief Medical Officer, DirectorPurchase (P): 1,000 @ $3.10EDGAR
2025-02-044Owens David — Chief Medical Officer, DirectorPurchase (P): 1,000 @ $2.98EDGAR
2025-01-294Owens David — Chief Medical Officer, DirectorPurchase (P): 1,500 @ $2.70EDGAR

Recent 8-K events — Nexalin Technology, Inc.

FiledFormItems reportedSource
2026-08-218-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-208-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-178-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-08-118-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-07-298-K1.01 — Entry into a Material Definitive AgreementEDGAR
2026-07-278-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-06-178-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-198-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-228-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-258-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=NXL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →